Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | FER | P16591 | 1/20 | 0.47 |
| ▸ | LTK | P29376 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619605 | 1.00 | IDO1 (0.50) | IDO1TDO2TDP1LRRK2MAOA | |
| SCHEMBL14515139 | 1.00 | IDO1 (0.50) | IDO1TDO2TDP1LRRK2MAOA | |
| SCHEMBL14515157 | 0.83 | CCNB2 (0.60) | LRRK2MAPTMEN1KMT2APDPK1 | |
| SCHEMBL5618358 | 0.83 | CCNB2 (0.60) | LRRK2MAPTMEN1KMT2APDPK1 | |
| SCHEMBL5618363 | 0.83 | CCNB2 (0.60) | LRRK2MAPTMEN1KMT2APDPK1 | |
| SCHEMBL7006381 | 0.81 | TDP1 (0.69) | IDO1TDO2TDP1LRRK2MAOA | |
| SCHEMBL2829329 | 0.78 | TDP1 (0.50) | IDO1TDO2TDP1LRRK2MAOA | |
| SCHEMBL1465398 | 0.78 | TDP1 (0.54) | IDO1TDO2TDP1LRRK2MAOA | |
| SCHEMBL1466156 | 0.78 | TDP1 (0.54) | IDO1TDO2TDP1LRRK2MAOA | |
| SCHEMBL2829327 | 0.78 | TDP1 (0.50) | IDO1TDO2TDP1LRRK2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214700-B2 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | SUGEN INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20040039196-A1 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | SUGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| US-20030216462-A1 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | SUGEN, INC. | 2003-11-20 | — | — | US | disclosed |
| US-20020028828-A1 | (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors | SUGEN, INC. | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028828-A1 | (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors | MAPKAPK2, MAPKAPK3, MAP3K2 | IDO1 1262/4885TDO2 1921/4885TDP1 2581/4885 |
| US-20040039196-A1 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | MAPKAPK2, MAPKAPK3, MAP3K2 | IDO1 1262/4885TDO2 1921/4885TDP1 2581/4885 |
| US-20030216462-A1 | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors | MAPKAPK2, MAPKAPK3, MAP3K2 | IDO1 1262/4885TDO2 1921/4885TDP1 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.